Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COM Direxion Auspice Broad Commodity Strategy ETF	$27.85 +0.5%	$27.99	$27.46 ▼ $29.63	$181.00M	0.19	57,478 shs	179,654 shs
MBX MBX Biosciences	$14.33 +1.3%	$12.51	$4.81 ▼ $27.50	$481.40M	N/A	328,877 shs	280,074 shs
ONC BeOne Medicines	$313.67 -0.1%	$279.28	$170.99 ▼ $330.63	$34.38B	0.27	412,149 shs	156,851 shs
SCYB Schwab High Yield Bond ETF	$26.59 +0.8%	$26.39	$24.73 ▼ $26.79	$1.28B	0.33	477,836 shs	1.06 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COM Direxion Auspice Broad Commodity Strategy ETF	0.00%	+1.02%	-2.01%	-1.87%	-2.96%
MBX MBX Biosciences	0.00%	-2.65%	+9.98%	+17.94%	+1,432,999,900.00%
ONC BeOne Medicines	0.00%	-2.39%	+5.81%	+29.92%	+31,366,999,900.00%
SCYB Schwab High Yield Bond ETF	0.00%	+0.53%	+0.57%	+2.31%	+0.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COM Direxion Auspice Broad Commodity Strategy ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	1.9525 of 5 stars	3.5	0.0	0.0	0.0	1.1	1.7	0.6
ONC BeOne Medicines	0.7525 of 5 stars	1.5	0.0	0.0	0.0	2.3	1.7	0.6
SCYB Schwab High Yield Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COM Direxion Auspice Broad Commodity Strategy ETF	0.00	N/A	N/A	N/A
MBX MBX Biosciences	3.00	Buy	$37.63	162.56% Upside
ONC BeOne Medicines	3.00	Buy	$330.89	5.49% Upside
SCYB Schwab High Yield Bond ETF	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MBX, ONC, SCYB, and COM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$350.00 ➝ $365.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COM Direxion Auspice Broad Commodity Strategy ETF	N/A	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	$3.81B	9.02	N/A	N/A	$34.10 per share	9.20
SCYB Schwab High Yield Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COM Direxion Auspice Broad Commodity Strategy ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	441.79	N/A	-3.89%	-1.22%	-0.72%	N/A
SCYB Schwab High Yield Bond ETF	N/A	N/A	60.28	∞	N/A	N/A	N/A	N/A	N/A

Latest MBX, ONC, SCYB, and COM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COM Direxion Auspice Broad Commodity Strategy ETF	$0.99	3.55%	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SCYB Schwab High Yield Bond ETF	$1.86	7.00%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COM Direxion Auspice Broad Commodity Strategy ETF	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A
ONC BeOne Medicines	0.04	1.95	1.72
SCYB Schwab High Yield Bond ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COM Direxion Auspice Broad Commodity Strategy ETF	N/A
MBX MBX Biosciences	N/A
ONC BeOne Medicines	48.55%
SCYB Schwab High Yield Bond ETF	N/A

Insider Ownership

Company	Insider Ownership
COM Direxion Auspice Broad Commodity Strategy ETF	N/A
MBX MBX Biosciences	52.19%
ONC BeOne Medicines	6.62%
SCYB Schwab High Yield Bond ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COM Direxion Auspice Broad Commodity Strategy ETF	N/A	6.50 million	N/A	Not Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
SCYB Schwab High Yield Bond ETF	N/A	48.30 million	N/A	Not Optionable

MBX, ONC, SCYB, and COM Headlines

Recent News About These Companies

CSE Bulletin: Consolidation - Scryb Inc. (SCYB)

August 11, 2025 | newsfilecorp.comN

SCYB: Passive High Yield ETF From Schwab

July 16, 2025 | seekingalpha.com

Schwab High Yield Bond ETF declares $0.1527 dividend

July 1, 2025 | msn.com

7 Lowest Expense Ratio ETFs

June 10, 2025 | money.usnews.com

SCYB: Not The Time For High Yield

May 4, 2025 | seekingalpha.com

Schwab High Yield Bond ETF declares $0.1586 dividend

May 2, 2025 | seekingalpha.com

Schwab High Yield Bond ETF (SCYB) Dividend History

March 29, 2025 | nasdaq.com

Trend Tracker for (SCYB)

February 11, 2025 | news.stocktradersdaily.comN

(SCYB) Trading Signals

January 31, 2025 | news.stocktradersdaily.comN

These High-Yield Dividend Stocks Are Looking Better Than Bonds for Safety

January 27, 2025 | msn.com

When the Price of (SCYB) Talks, People Listen

January 20, 2025 | news.stocktradersdaily.comN

(SCYB) Investment Report

December 30, 2024 | news.stocktradersdaily.comN

When (SCYB) Moves Investors should Listen

December 19, 2024 | news.stocktradersdaily.comN

Schwab High Yield Bond ETF declares monthly distribution of $0.1489

December 3, 2024 | msn.com

(SCYB) Proactive Strategies

November 17, 2024 | news.stocktradersdaily.comN

Schwab High Yield Bond ETF declares monthly distribution of $0.1667

November 5, 2024 | msn.com

(SCYB) Long Term Investment Analysis

October 17, 2024 | news.stocktradersdaily.comN

Where are the Opportunities in (SCYB)

September 15, 2024 | news.stocktradersdaily.comN

Schwab High Yield Bond ETF declares monthly distribution of $0.3075

September 4, 2024 | msn.com

SCHO: A Low-Risk, High-Yield Pick To Boost Your Dividend Portfolio's Stability

August 29, 2024 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MBX, ONC, SCYB, and COM Company Descriptions

Direxion Auspice Broad Commodity Strategy ETF NYSEARCA:COM

$27.85 +0.13 (+0.47%)

Closing price 08/22/2025 04:10 PM Eastern

Extended Trading

$27.84 -0.01 (-0.02%)

As of 08/22/2025 04:10 PM Eastern

The Direxion Auspice Broad Commodity Strategy ETF (COM) is an exchange-traded fund that is based on the Auspice Broad Commodity index. The fund tracks a broad-market index consisting of 12 commodity futures contracts, weighted by historical volatility, which can toggle to cash based on momentum. The fund will also hold short-term fixed income securities as collateral. COM was launched on Mar 30, 2017 and is managed by Direxion.

MBX Biosciences NYSE:MBX

$14.33 +0.18 (+1.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.34 +0.01 (+0.03%)

As of 08/22/2025 06:52 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

BeOne Medicines NASDAQ:ONC

$313.67 -0.30 (-0.10%)

As of 08/22/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Schwab High Yield Bond ETF NYSEARCA:SCYB

$26.59 +0.20 (+0.76%)

Closing price 08/22/2025 04:10 PM Eastern

Extended Trading

$26.58 -0.02 (-0.06%)

As of 08/22/2025 07:59 PM Eastern

The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time